1. Market Research
  2. > Myeloproliferative Disorders - Pipeline Review, H1 2013

Myeloproliferative Disorders - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 171 pages

Myeloproliferative Disorders - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Myeloproliferative Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myeloproliferative Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloproliferative Disorders. Myeloproliferative Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Myeloproliferative Disorders.
- A review of the Myeloproliferative Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myeloproliferative Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Myeloproliferative Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myeloproliferative Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Myeloproliferative Disorders - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Myeloproliferative Disorders Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Myeloproliferative Disorders 11
Myeloproliferative Disorders Therapeutics under Development by Companies 13
Myeloproliferative Disorders Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Myeloproliferative Disorders Therapeutics - Products under Development by Companies 20
Myeloproliferative Disorders Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Myeloproliferative Disorders Therapeutics Development 23
Bristol-Myers Squibb Company 23
Sanofi-Aventis 24
AstraZeneca PLC 25
Eli Lilly and Company 26
Genentech, Inc. 27
Gilead Sciences, Inc. 28
Merck and Co., Inc. 29
Nanotherapeutics, Inc. 30
Novartis AG 31
Teva Pharmaceutical Industries Limited 32
Cell Therapeutics, Inc. 33
Celgene Corporation 34
Shire Plc 35
Incyte Corporation 36
Geron Corporation 37
Merck KGaA 38
Marshall Edwards, Inc. 39
Synta Pharmaceuticals Corp. 40
Italfarmaco S.p.A. 41
Celon Pharma Sp. z o.o. 42
Promedior, Inc. 43
Onconova Therapeutics, Inc 44
PharmaMar, S.A. 45
KaloBios Pharmaceuticals, Inc. 46
PharmaEssentia Corporation 47
miRagen Therapeutics, Inc. 48
EpiZyme, Inc. 49
Myeloproliferative Disorders - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 56
lestaurtinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
pacritinib - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
imetelstat sodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
panobinostat - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
cilengitide - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
anagrelide hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
pracinostat - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
momelotinib - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
ruxolitinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
ruxolitinib - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
peginterferon alfa-2b - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
ON-044580 - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
PRM-151 - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
KB-004 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
SAR-302503 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
SAR-302503 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
plitidepsin - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
Triapine - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
buparlisib - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
pomalidomide - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
AUY-922 - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
MGN-4893 - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
givinostat - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
simtuzumab - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
gandotinib - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
INCB-39110 - Drug Profile 111
Product Description 111
Mechanism of Action 111
RandD Progress 111
CPL-407-22 - Drug Profile 113
Product Description 113
Mechanism of Action 113
RandD Progress 113
EPZ-5676 - Drug Profile 114
Product Description 114
Mechanism of Action 114
RandD Progress 114
7j - Drug Profile 115
Product Description 115
Mechanism of Action 115
RandD Progress 115
ACG-812bF3 Enantiomers - Drug Profile 116
Product Description 116
Mechanism of Action 116
RandD Progress 116
Janus Kinase 2 Inhibitor - Drug Profile 117
Product Description 117
Mechanism of Action 117
RandD Progress 117
Myeloproliferative Disorders Therapeutics - Drug Profile Updates 118
Myeloproliferative Disorders Therapeutics - Discontinued Products 157
Myeloproliferative Disorders Therapeutics - Dormant Products 158
Myeloproliferative Disorders - Product Development Milestones 159
Featured News and Press Releases 159
Jun 17, 2013: Cell Therapeutics Announces Results From Pooled Data Analysis Of Completed Phase I And II Studies Of Pacritinib At EHA 2013 Congress 159
Jun 16, 2013: Geron Announces Presentation Of Updated Results From Imetelstat Phase II Trial In Essential Thrombocythemia At 18th EHA Congress 161
Jun 16, 2013: Incyte's Jakafi Improves Overall Survival In Phase III Trial Of Patients With Myelofibrosis 162
Jun 12, 2013: FDA Issues Prescribing Information For Incyte's Ruxolitinib With Expanded Dosing Guidance And New Safety Information 163
Jun 10, 2013: Cell Therapeutics Presents Results From Phase I And II Studies Of Pacritinib At 18th Congress Of EHA Annual Meeting 164
Jun 04, 2013: Incyte Presents Results From Ongoing Phase I/II Clinical Trial Of Jakafi At ASCO 2013 Annual Meeting 165
May 17, 2013: Sanofi Reports Positive Topline Results From Pivotal Phase III Study For JAK2 Inhibitor SAR302503 In Myelofibrosis 166
Apr 25, 2013: Geron Updates Imetelstat Development Strategy, Including Progress Of Investigator-Sponsored Study In Myelofibrosis 166
Apr 01, 2013: Indian Supreme Court Denies Patent For Novartis's Updated Version Of Leukemia Drug Glivec 168
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 168
Appendix 170
Methodology 170
Coverage 170
Secondary Research 170
Primary Research 170
Expert Panel Validation 170
Contact Us 171
Disclaimer 171

List of Tables


Number of Products Under Development for Myeloproliferative Disorders, H1 2013 11
Products under Development for Myeloproliferative Disorders - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Sanofi-Aventis, H1 2013 24
Eli Lilly and Company, H1 2013 26
Genentech, Inc., H1 2013 27
Gilead Sciences, Inc., H1 2013 28
Merck and Co., Inc., H1 2013 29
Nanotherapeutics, Inc., H1 2013 30
Novartis AG, H1 2013 31
Teva Pharmaceutical Industries Limited, H1 2013 32
Cell Therapeutics, Inc., H1 2013 33
Celgene Corporation, H1 2013 34
Shire Plc, H1 2013 35
Incyte Corporation, H1 2013 36
Geron Corporation, H1 2013 37
Merck KGaA, H1 2013 38
Marshall Edwards, Inc., H1 2013 39
Italfarmaco S.p.A., H1 2013 41
Celon Pharma Sp. z o.o., H1 2013 42
Promedior, Inc., H1 2013 43
Onconova Therapeutics, Inc, H1 2013 44
PharmaMar, S.A., H1 2013 45
KaloBios Pharmaceuticals, Inc., H1 2013 46
PharmaEssentia Corporation, H1 2013 47
miRagen Therapeutics, Inc., H1 2013 48
EpiZyme, Inc., H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 55
Myeloproliferative Disorders Therapeutics - Drug Profile Updates 118
Myeloproliferative Disorders Therapeutics - Discontinued Products 157
Myeloproliferative Disorders Therapeutics - Dormant Products 158

List of Figures


Number of Products under Development for Myeloproliferative Disorders, H1 2013 11
Products under Development for Myeloproliferative Disorders - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 50
Assessment by Route of Administration, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Molecule Type, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.